Wells Fargo Lifts PT on Liquidia Corporation (LQDA) to $51 From $44 – Here’s Why

Liquidia Corporation (NASDAQ:LQDA) is one of the best high growth healthcare stocks to buy now. Wells Fargo raised the price target on Liquidia Corporation (NASDAQ:LQDA) to $51 from $44 on March 23, reiterating an Overweight rating on the shares and telling investors that it believes the pulmonary hypertension market is poised to change. It added that with key opinion leader feedback from a Respimat developer, and counter to current market sentiment, the firm sees the company’s L606 as competitive with Insmed’s TPIP.

Liquidia Corporation (NASDAQ:LQDA) also received a rating update from Oppenheimer on March 12. The firm lifted the price target on the stock to $19 from $16, reiterating an Underperform rating on the shares and giving credit to the company’s team for executing a strong early launch of YUTREPIA in pulmonary arterial hypertension/pulmonary hypertension associated with interstitial lung disease. It posted net product sales of $148.3 million in fiscal year 2025 despite what it continues to hear from physicians on YUTREPIA not being meaningfully differentiated. Oppenheimer believes that the immediate success speaks more to the growing need in PAH/PH-ILD, which the firm underestimated.

Liquidia Corporation (NASDAQ:LQDA) is a holding company involved in, through its subsidiary, developing and commercializing biopharmaceutical products and novel product development used in PRINT technology.

While we acknowledge the risk and potential of LQDA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than LQDA and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.

Disclosure: None. Follow Insider Monkey on Google News.